Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
- COVID-19 vaccine experiments conducted on monkeys in Thailand were a success.
- After being given two doses of candidate vaccine, the monkeys had high levels of antibody against COVID-19.
- It is possible that in September the search for volunteers in the human trials will be announced
A research team from the National Primate Research Center of Chulalongkorn University in Thailand reveals that the COVID-19 vaccine is a successful experiment on monkeys and that human trials are likely to begin as well.
The research team is just waiting for FDA approval before conducting human trials for the vaccine against novel coronavirus, according to Prof. Suttipong Wacharasindhu, the director of Chulalongkorn Hospital, and Prof. Kiat Ruxrungtham, director of the Chulalongkorn vaccine research center at a gpress conference held on Sunday, July 12th.
Candidate COVID-19 vaccine is first injected on macaque monkeys on May 23, 2020. All monkeys are said to be in good condition and have “satisfactory immune responses to the virus, according to Higher Education, Science, Research and Innovations Minister Suvit Maesincee.
And last month the monkeys were given a second dose of the vaccine. They contained high levels of COVID-19 antibodies.
According to Chutitorn Ketloy, a research team member, macaque monkeys that were vaccinated in May and June had immunity to COVID-19. Their antibody levels reached 5,120 after the second dose.
Laboratory mice injected with candidate vaccine had antibody levels of up to 40,960. It appears that the development of the vaccine being developed decreases as the size of the test subject increases.
“This is a significant result, as we now understand that the antibody response will drop by 5-10 times when the vaccine is administered on humans. But even with such a decrease, immunity to the disease can be achieved as long as the antibody response measures above 1,000, which is the level we hope to see in the human trial,” according to a research team member.
According to the research team, it is possible that in September they will announce the search for volunteers for the human trials to be conducted in three parts. The first phase of the trial is expected to be completed before the end of 2020.
And if the three human trials are successful, the COVID-19 vaccine will be available for those in the third quarter of next year.